Related Experiment Videos
Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivity
M A L Moneef1, B T Sherwood, K J Bowman
1Department of Cancer Studies and Molecular Medicine, Hodgkin Building, University of Leicester, Lancaster Road, PO Box 138, Leicester LE1 9HN, UK.
British Journal of Cancer
|December 17, 2003
Summary
Predicting bladder cancer radiosensitivity is key for effective treatment. The alkaline comet assay (ACA) accurately measures DNA damage, correlating strongly with cell killing and predicting patient response to radiotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy Research
Background:
- Invasive bladder cancer treatment in the UK relies on radiotherapy or cystectomy.
- Radiotherapy response rates are suboptimal, with approximately 50% of patients not responding.
- Predicting tumour radiosensitivity could personalize treatment and improve outcomes.
Purpose of the Study:
- To evaluate the alkaline comet assay (ACA) as a predictive tool for bladder cancer radiosensitivity.
- To correlate DNA damage assessed by ACA with cell survival following radiation exposure.
- To assess the potential clinical application of ACA in bladder cancer treatment selection.
Main Methods:
- Utilized six human bladder cancer cell lines with varying radiosensitivities.
- Assessed radiogenic DNA damage using the alkaline comet assay (ACA).
- Compared comet formation and residual DNA damage with cell survival and radiosensitivity.
Main Results:
- Strong correlation (R2>0.96) observed between comet formation extent and cancer cell killing.
- Radiosensitive cell lines exhibited a greater response in the ACA.
- Residual DNA damage correlated with survival fraction at 2 Gy in most cell lines.
- ACA predicted a wide range of radiosensitivities in human bladder tumour biopsy samples.
Conclusions:
- The alkaline comet assay (ACA) is a reliable predictor of bladder cancer cell radiosensitivity at low radiation doses.
- ACA demonstrates potential for clinical application in guiding bladder cancer treatment decisions.
- Personalized radiotherapy selection based on ACA results could improve treatment efficacy.